Skip to main content
. Author manuscript; available in PMC: 2017 Nov 21.
Published in final edited form as: Mol Pharm. 2017 Oct 25;14(11):3709–3717. doi: 10.1021/acs.molpharmaceut.7b00469

Table 3.

Pharmacodynamic parameters of phase II antioxidant gene expression estimated from the designated PK-PD model shown in Figure 1.

mRNA Emax (CV%) EC50(μg/mL) (CV%) τ (h) (CV%) kin (h-1) (CV%)
Ho1 13.2 (42.9) 0.368 (45.7) 0.767 (fixed) 1.306 (57.7)
Nqo1 7.330 (35.6) 1.738 (42.3) 0.710 (fixed) 1.436 (79.3)
Ugt1a1 8.520 (63.2) 1.360 (62.2) 0.751 (fixed) 1.771 (70.2)